FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220993778> ?p ?o ?g. }

• W4220993778 endingPage "1821" @default.
• W4220993778 startingPage "1812" @default.
• W4220993778 abstract "Abstract Objective This study was undertaken to update and evaluate long‐term seizure outcomes in patients with autoimmune encephalitis (AE) based on a large cohort study with long follow‐up. Methods In this prospective observational registry study, we analyzed data from patients with AE mediated by common types of neuronal surface antibodies (anti‐ N ‐methyl‐ d ‐aspartate receptor [NMDAR], anti‐leucine‐rich glioma‐inactivated 1 [LGI1]/contactin‐associated protein‐like 2 [Caspr2], anti‐γ‐aminobutyric acid type B receptor [GABA B R]). All patients were recruited from the Department of Neurology at West China Hospital between October 2011 and June 2019, and data were collected prospectively on their demographic and clinical characteristics, treatment strategy, and seizure outcomes, with a median follow‐up of 42 months (range = 6–93 months). Potential risk factors associated with seizure recurrence were also assessed. Results Of 320 AE patients, 75.9% had acute seizures, among whom >90% of patients had their last seizure within 12 months of disease onset. During our follow‐up, 21 (9.3%) patients experienced seizure recurrence. Patients with anti‐GABA B R encephalitis had a higher cumulative incidence of seizure recurrence than those with anti‐NMDAR (log‐rank p = .03) or anti‐LGI1/Caspr2 encephalitis (log‐rank p = .04). Among patients with anti‐NMDAR encephalitis, women had a significantly higher cumulative incidence of seizure recurrence than men (log‐rank p = .01). Interictal epileptiform discharges (IEDs) or seizures captured on continuous electroencephalogram (EEG) in the acute phase were identified as potential risk factors for seizure recurrence ( p = .04, p = .007). Among 163 patients with ≥24 months of follow‐up, five (3.1%) showed persistent seizures and required ongoing antiseizure medications despite aggressive immunotherapy. Significance Seizure recurrence occurred in a small number of patients and chronic epilepsy occurred in 3.1% of patients during prolonged follow‐up. Across all types of AE, risk factors for seizure recurrence were IEDs or seizures captured on EEG in the acute phase; for anti‐NMDAR encephalitis, female sex was also a risk factor." @default.
• W4220993778 created "2022-04-03" @default.
• W4220993778 creator A5009613920 @default.
• W4220993778 creator A5027448540 @default.
• W4220993778 creator A5030740758 @default.
• W4220993778 creator A5058217577 @default.
• W4220993778 creator A5065990541 @default.
• W4220993778 creator A5067692406 @default.
• W4220993778 creator A5080140259 @default.
• W4220993778 date "2022-04-16" @default.
• W4220993778 modified "2023-10-17" @default.
• W4220993778 title "Long‐term seizure outcomes in patients with autoimmune encephalitis: A prospective observational registry study update" @default.
• W4220993778 cites W1856414226 @default.
• W4220993778 cites W2070162113 @default.
• W4220993778 cites W2110026843 @default.
• W4220993778 cites W2123159874 @default.
• W4220993778 cites W2129658473 @default.
• W4220993778 cites W2146199022 @default.
• W4220993778 cites W2153926223 @default.
• W4220993778 cites W2169403125 @default.
• W4220993778 cites W2280783985 @default.
• W4220993778 cites W2342000669 @default.
• W4220993778 cites W2508852886 @default.
• W4220993778 cites W2594644573 @default.
• W4220993778 cites W2595114075 @default.
• W4220993778 cites W2766065003 @default.
• W4220993778 cites W2766822273 @default.
• W4220993778 cites W2791304973 @default.
• W4220993778 cites W2797472478 @default.
• W4220993778 cites W2899012725 @default.
• W4220993778 cites W2937160316 @default.
• W4220993778 cites W2937321881 @default.
• W4220993778 cites W2956177188 @default.
• W4220993778 cites W2960193178 @default.
• W4220993778 cites W2972292676 @default.
• W4220993778 cites W3017221604 @default.
• W4220993778 cites W3024690067 @default.
• W4220993778 cites W3034212049 @default.
• W4220993778 cites W3035539023 @default.
• W4220993778 cites W3044703934 @default.
• W4220993778 cites W3131463167 @default.
• W4220993778 cites W3134200638 @default.
• W4220993778 cites W3180930680 @default.
• W4220993778 cites W3201835080 @default.
• W4220993778 doi "https://doi.org/10.1111/epi.17245" @default.
• W4220993778 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35357695" @default.
• W4220993778 hasPublicationYear "2022" @default.
• W4220993778 type Work @default.
• W4220993778 citedByCount "14" @default.
• W4220993778 countsByYear W42209937782022 @default.
• W4220993778 countsByYear W42209937782023 @default.
• W4220993778 crossrefType "journal-article" @default.
• W4220993778 hasAuthorship W4220993778A5009613920 @default.
• W4220993778 hasAuthorship W4220993778A5027448540 @default.
• W4220993778 hasAuthorship W4220993778A5030740758 @default.
• W4220993778 hasAuthorship W4220993778A5058217577 @default.
• W4220993778 hasAuthorship W4220993778A5065990541 @default.
• W4220993778 hasAuthorship W4220993778A5067692406 @default.
• W4220993778 hasAuthorship W4220993778A5080140259 @default.
• W4220993778 hasConcept C118552586 @default.
• W4220993778 hasConcept C120665830 @default.
• W4220993778 hasConcept C121332964 @default.
• W4220993778 hasConcept C126322002 @default.
• W4220993778 hasConcept C16568411 @default.
• W4220993778 hasConcept C17755696 @default.
• W4220993778 hasConcept C187212893 @default.
• W4220993778 hasConcept C188816634 @default.
• W4220993778 hasConcept C201903717 @default.
• W4220993778 hasConcept C203014093 @default.
• W4220993778 hasConcept C2522874641 @default.
• W4220993778 hasConcept C2778186239 @default.
• W4220993778 hasConcept C2780874087 @default.
• W4220993778 hasConcept C2781460105 @default.
• W4220993778 hasConcept C61511704 @default.
• W4220993778 hasConcept C71924100 @default.
• W4220993778 hasConcept C72563966 @default.
• W4220993778 hasConcept C83455156 @default.
• W4220993778 hasConcept C88879693 @default.
• W4220993778 hasConceptScore W4220993778C118552586 @default.
• W4220993778 hasConceptScore W4220993778C120665830 @default.
• W4220993778 hasConceptScore W4220993778C121332964 @default.
• W4220993778 hasConceptScore W4220993778C126322002 @default.
• W4220993778 hasConceptScore W4220993778C16568411 @default.
• W4220993778 hasConceptScore W4220993778C17755696 @default.
• W4220993778 hasConceptScore W4220993778C187212893 @default.
• W4220993778 hasConceptScore W4220993778C188816634 @default.
• W4220993778 hasConceptScore W4220993778C201903717 @default.
• W4220993778 hasConceptScore W4220993778C203014093 @default.
• W4220993778 hasConceptScore W4220993778C2522874641 @default.
• W4220993778 hasConceptScore W4220993778C2778186239 @default.
• W4220993778 hasConceptScore W4220993778C2780874087 @default.
• W4220993778 hasConceptScore W4220993778C2781460105 @default.
• W4220993778 hasConceptScore W4220993778C61511704 @default.
• W4220993778 hasConceptScore W4220993778C71924100 @default.
• W4220993778 hasConceptScore W4220993778C72563966 @default.
• W4220993778 hasConceptScore W4220993778C83455156 @default.
• W4220993778 hasConceptScore W4220993778C88879693 @default.
• W4220993778 hasFunder F4320321001 @default.

• next